Newsletter Subject

Breakthrough New Drug Could Send Tiny Stock Soaring

From

paradigmpressgroup.com

Email Address

info@mb.paradigmpressgroup.com

Sent On

Fri, Jul 21, 2023 05:31 PM

Email Preheader Text

Is This New Drug The End Of Arthritis? Breakthrough New Drug Could Send Tiny Stock Soaring Take a lo

Is This New Drug The End Of Arthritis? [American Death Angel Summit] July 21, 2023 [UNSUBSCRIBE]( Breakthrough New Drug Could Send Tiny Stock Soaring [Matt Insley] MATT INSLEY Reader, [Meet the tiny stock behind what I call the “Humira Killer”…]( Take a look: [Click here to learn more]( [Click here for details on the “Humira Killer”…]( As you may know, Humira is the best-selling drug in the world… In total, since 2002, AbbVie (the company behind Humira) has made over $200 billion in sales from the drug. And that’s because arthritis (which Humira treats) is one of the biggest and most common diseases in America… It affects 54 million people, or well over 20% of our country’s adult population. Yet as you’re about to see, despite its popularity, Humira has a number of huge shortcomings: It’s not effective in many cases… it has potentially dangerous side effects… and it requires regular injections. [This breakthrough new drug is being designed to solve all of those problems…]( - It’s demonstrated in pre-clinical trials to be 70% more effective than Humira… - It does so without being shown to cause any serious side effects… - And best of all, it doesn’t require any injections – the dosing is done orally. Conservatively speaking, if [this pre-clinical drug]( manages to capture even 1/10th of Humira’s market share, that’d be more than enough to send the tiny stock behind it soaring 20-fold. And it all begins with an upcoming announcement expected just days from now. That’s why I’m urging you to act right away… [Click here for details.]( Regards, [Matt Insley] Matt Insley Executive Publisher, Paradigm Press © 2023 Paradigm Press, LLC. 808 Saint Paul Street, Baltimore MD 21202. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your American Death Angel Summit e-mail subscription and associated external offers sent from American Death Angel Summit, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@paradigmpressgroup.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. American Death Angel Summit is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your American Death Angel Summit subscription, you can ensure its arrival in your mailbox by [whitelisting American Death Angel Summit.](

Marketing emails from paradigmpressgroup.com

View More
Sent On

08/12/2024

Sent On

08/12/2024

Sent On

07/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.